Acadia Healthcar Stock Price, News & Analysis

Acadia Healthcare (NASDAQ: ACHC) has announced the pricing of its private offering of $550 million in senior notes due 2033, representing a $50 million increase from its previous announcement. The notes will bear interest at 7.375% per year, payable semi-annually on March 15 and September 15, starting September 15, 2025.

The offering is expected to close on March 10, 2025, subject to customary conditions. The notes were offered at 100.000% of the principal amount and will mature on March 15, 2033. Acadia plans to use the proceeds to prepay outstanding borrowings under its existing senior secured revolving line of credit.

The notes are being offered exclusively to qualified institutional buyers under Rule 144A and non-U.S. persons under Regulation S of the Securities Act.

Acadia Healthcare (NASDAQ: ACHC) has announced a private offering of $500 million in senior notes due 2033. The company plans to use the proceeds to prepay a portion of its outstanding borrowings under its existing senior secured revolving line of credit.

The notes will only be offered to 'qualified institutional buyers' under Rule 144A of the Securities Act and non-U.S. persons under Regulation S. The notes have not been registered under the Securities Act of 1933 and cannot be offered or sold in the United States except under applicable exemptions.

Acadia Healthcare (NASDAQ: ACHC) reported strong Q4 2024 results with revenue of $774.2 million, up 4.2% year-over-year. Same facility revenue increased 4.7%, driven by a 3.2% rise in patient days and 1.4% growth in revenue per patient day.

The company achieved net income of $32.6 million ($0.35 per diluted share) and adjusted income of $59.2 million ($0.64 per diluted share). Q4 Adjusted EBITDA was $153.1 million, including a $14.3 million professional liability reserve adjustment and $5.0 million impact from facility closure.

Notable developments include adding 577 newly licensed beds in Q4, completing construction of approximately 1,300 beds in 2024, and announcing a new $300 million share repurchase authorization. The company expanded its CTC network to 163 centers across 33 states, treating over 72,000 patients daily.

Acadia Healthcare (NASDAQ: ACHC) has announced its participation in three major investor conferences during March 2025:

1. Raymond James 46th Annual Institutional Investors Conference in Orlando, Florida (March 2-5), presenting on March 4 at 8:05 a.m. ET

2. Leerink Partners 2025 Global Healthcare Conference in Miami, Florida (March 10-12), presenting on March 11 at 2:20 p.m. ET

3. Barclays 27th Annual Global Healthcare Conference in Miami, Florida (March 11-13), presenting on March 12 at 9:30 a.m. ET

All presentations will be available via live webcast on Acadia Healthcare's website through the Investors section. Replays will remain accessible for 30 days following the events.

Acadia Healthcare (NASDAQ: ACHC) has announced it will release its fourth quarter and year-end 2024 financial results on Thursday, February 27, 2025, after market close. The company will host a conference call with institutional investors and analysts at 9:00 a.m. ET on Friday, February 28, 2025. A live webcast of the conference call will be accessible through the 'Investors' section of Acadia's website and will remain available for 30 days.

Acadia Healthcare (NASDAQ: ACHC) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco, California. The company will deliver a presentation that will be available via webcast on Tuesday, January 14, 2025, at 1:30 p.m. Pacific Time/3:30 p.m. Central Time.

Investors and interested parties can access the live webcast through the 'Investors' section of Acadia Healthcare's website (www.acadiahealthcare.com). A replay of the presentation will remain accessible on the company's website for 30 days following the event.

Acadia Healthcare (NASDAQ: ACHC) has announced its participation in the Stephens Annual Investment Conference, taking place from November 19-21, 2024, in Nashville, Tennessee. The company will deliver a presentation on Wednesday, November 20, 2024, at 11:00 a.m. Eastern Time (10:00 a.m. Central Time).

The presentation will be accessible via a live webcast on Acadia Healthcare's website under the 'Investors' section. A replay of the presentation will remain available on the company's website for 30 days following the event.

Acadia Healthcare reported strong Q3 2024 results with revenue of $815.6 million, up 8.7% year-over-year. Same facility revenue increased 8.6%, driven by a 3.6% increase in revenue per patient day and 4.7% growth in patient days. Net income reached $68.1 million ($0.74 per share), while adjusted income was $84.1 million ($0.91 per share). Adjusted EBITDA grew 10.5% to $194.3 million. The company expanded its facilities, adding 15 beds and five new CTCs during Q3, now operating 164 CTCs across 32 states. Acadia updated its 2024 guidance, projecting revenue of $3.15-3.165 billion and adjusted EBITDA of $725-735 million.

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) has announced the acquisition of three opioid treatment program clinics in South Carolina. These clinics, formerly operated by Recovery Concepts, Recovery Concepts of the Carolina Upstate, and Clear Skye Treatment Center, will be rebranded as part of Acadia's Comprehensive Treatment Center (CTC) service line. The facilities, now named Clinton, Easley, and Ridgeland Comprehensive Treatment Centers, are Acadia's first CTCs in South Carolina and will offer care to all patients, including those covered by Medicaid.

This acquisition follows Acadia's recent expansion in North Carolina, bringing the Company's CTC division to 165 locations across 33 states, treating over 72,000 patients daily. The CTCs provide medication-assisted treatment programs combining behavioral therapy and medication to treat opioid use disorders, along with comprehensive support services including medical, counseling, vocational, and educational assistance.